

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Form name	Number of respondents	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total burden hours
Institution/Loan Repayment Employment Form .....	*215	1	215	1.00	215.00
Authorization to Release Information Form .....	215	1	215	.25	53.75
Disadvantaged Background Form .....	215	1	215	.20	43.00
Total .....	860				526.75

\* Respondents for this form is the institution on behalf of the applicant.

HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency's functions, (2) the accuracy of the estimated burden, (3) ways to enhance the quality, utility, and clarity of the information to be collected, and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

**Maria G. Button,**

Director, Executive Secretariat.

[FR Doc. 2023-19054 Filed 9-1-23; 8:45 am]

BILLING CODE 4165-15-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Meeting of the National Vaccine Advisory Committee**

**AGENCY:** Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) hereby gives notice that the National Vaccine Advisory Committee (NVAC) will hold an in-person meeting. The meeting will be open to the public and public comment will be heard during the meeting.

**DATES:** The meeting will be held September 21-22, 2023. The confirmed meeting times and agenda will be posted on the NVAC website at <http://www.hhs.gov/nvpo/nvac/meetings/index.html> as soon as they become available.

**ADDRESSES:** Instructions regarding attending this meeting will be posted online at: <http://www.hhs.gov/nvpo/nvac/meetings/index.html> at least one week prior to the meeting. Pre-registration is required for those who wish to attend the meeting in person or

participate in public comment. Please register at <http://www.hhs.gov/nvpo/nvac/meetings/index.html>.

**FOR FURTHER INFORMATION CONTACT:** Ann Aikin, Acting Designated Federal Officer, Office of Infectious Disease and HIV/AIDS Policy, U.S. Department of Health and Human Services, Tower Building, Room, 1101 Wootton Parkway, Rockville, MD 20852. Email: [nvac@hhs.gov](mailto:nvac@hhs.gov). Phone: 202-795-7697.

**SUPPLEMENTARY INFORMATION:** Pursuant to section 2101 of the Public Health Service Act (42 U.S.C. 300aa-1), the Secretary of HHS was mandated to establish the National Vaccine Program to achieve optimal prevention of human infectious diseases through immunization and to achieve optimal prevention against adverse reactions to vaccines. The NVAC was established to provide advice and make recommendations to the Director of the National Vaccine Program on matters related to the Program's responsibilities. The Assistant Secretary for Health serves as Director of the National Vaccine Program.

During this meeting, NVAC will hear presentations to support the recent charges on innovation and safety from Admiral Rachel L. Levine, MD, the Assistant Secretary for Health and Director of the National Vaccine Program. NVAC will also hear presentations on the actions and strategies taken to better address the unique vaccination needs of people with disabilities, respiratory disease prevention plans for the upcoming fall season, and updates on climate change vaccines. Please note that agenda items are subject to change, as priorities dictate. Information on the final meeting agenda will be posted prior to the meeting on the NVAC website: <http://www.hhs.gov/nvpo/nvac/index.html>.

Members of the public will have the opportunity to provide comment at the NVAC meeting during the public comment period designated on the agenda. Public comments made during the meeting will be limited to three minutes per person to ensure time is

allotted for all those wishing to speak. Members of the public may also submit written comments. Written comments should not exceed three pages in length. Individuals planning to submit comments should email their written comments or their request to provide a comment during the meeting to [nvac@hhs.gov](mailto:nvac@hhs.gov) at least five business days prior to the meeting.

Dated: August 7, 2023.

**Ann Aikin,**

Acting Designated Federal Official, Office of the Assistant Secretary for Health.

[FR Doc. 2023-18994 Filed 9-1-23; 8:45 am]

BILLING CODE 4150-44-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Office of the Secretary**

**Findings of Research Misconduct**

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Findings of research misconduct have been made against Ivana Frech, Ph.D. (formerly Ivana De Domenico) (Respondent), former Assistant Professor, Department of Internal Medicine, University of Utah (UU) School of Medicine. Respondent engaged in research misconduct in research supported by U.S. Public Health Service (PHS) funds, specifically National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), grants R01 DK070947, R01 DK090257, and R01 DK030534, National Institute of General Medical Sciences (NIGMS), NIH, grant P50 GM082545, National Institute of Allergy and Infectious Diseases (NIAID), NIH, grant R01 AI051174, and National Heart, Lung, and Blood Institute (NHLBI), NIH, grant R01 HL026922. The administrative actions, including debarment for a period of three (3) years, were implemented beginning on August 21, 2023, and are detailed below.

**FOR FURTHER INFORMATION CONTACT:**

Sheila Garrity, JD, MPH, MBA, Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453-8200.

**SUPPLEMENTARY INFORMATION:** Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

*Ivana Frech, Ph.D. (formerly Ivana De Domenico), University of Utah:* Based on the evidence and findings of an investigation conducted by UU, ORI's oversight review of UU's investigation, and additional analysis conducted by ORI during its oversight review, ORI found that Ivana Frech, Ph.D. (formerly Ivana De Domenico), former Assistant Professor, Department of Internal Medicine, UU School of Medicine, engaged in research misconduct under 42 CFR part 93 in research supported by PHS funds, specifically NIDDK, NIH, grants R01 DK070947, R01 DK090257, and R01 DK030534, NIGMS, NIH, grant P50 GM082545, NIAID, NIH, grant R01 AI051174, and NHLBI, NIH, grant R01 HL026922.

ORI found by a preponderance of the evidence that Respondent intentionally, knowingly, or recklessly falsified and/or fabricated western blot and autoradiogram images related to mechanisms of cellular iron regulation by reusing, relabeling, and manipulating images to falsely report data in eight (8) figures included in the following three (3) PHS-supported published papers:

- Two Distinct Modes of ESCRT-III Recognition are Required for VPS4 Functions in Lysosomal Protein Targeting and HIV-1 Budding. *Dev Cell*. 2008 Jul;15(1):62-73. doi: 10.1016/j.devcel.2008.05.014 (hereafter referred to as "*Dev. Cell 2008*").
- The Role of Ubiquitination in Hepcidin-independent and Hcpidin-dependent Degradation of Ferroportin. *Cell Metab*. 2011 Nov 2;14(5):635-46. doi: 10.1016/j.cmet.2011.09.008 (hereafter referred to as "*Cell Met. Nov. 2011*") Retracted: *Cell Met*. 2012 Jun 6;15(6):927. doi: 10.1016/j.cmet.2012.04.107.
- Decoupling Ferritin Synthesis from Free Cytosolic Iron Results in Ferritin Secretion. *Cell Metab*. 2011 Jan 5;13(1):57-67. doi: 10.1016/j.cmet.2010.12.003 (hereafter referred to as "*Cell Met. Jan. 2011*"). Retracted: *Cell Met*. 2012 Jun 6;15(6):927. doi: 10.1016/j.cmet.2012.04.012.

ORI found that these acts constitute a significant departure from accepted practices of the relevant research community. Specifically, ORI found by a preponderance of the evidence that Respondent engaged in research

misconduct by intentionally, knowingly, or recklessly falsifying and/or fabricating:

- a western blot image in Figure 5B (right bottom panel) of *Dev. Cell* 2008 by reusing and relabeling an image of three western blot bands to represent the results of different experiments
- western blot images in Figure 1C (top and bottom panels) of *Cell Met. Nov. 2011* by reusing and relabeling an image of western blot bands to represent the results of two different experiments
- western blot images in Figures 1D and 3 of *Cell Met. Nov. 2011* by reusing and relabeling one image to represent the results of two different experiments
- western blot images in Figures 2Aii and 2B of *Cell Met. Nov. 2011* by reusing and relabeling one image as representing the results of two different experiments
- western blot images in Figures 2Aii and 5 of *Cell Met. Nov. 2011* by reusing and relabeling one image as representing the results of two different experiments
- images in Figure 4B (top and bottom left panels) of *Cell Met. Jan. 2011* by reusing and relabeling an image of an autoradiogram to misrepresent the reported experimental conditions and results

The following administrative actions have been implemented:

- (1) For a period of three (3) years, beginning on August 21, 2023, Respondent is debarred from participating in "covered transactions" as defined in 42 CFR 180.200 and procurement transactions covered under the Federal Acquisition Regulation (48 CFR chapter 1).
- (2) Respondent is prohibited from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years, beginning on August 21, 2023.
- (3) In accordance with 42 CFR 93.407(a)(1) and 93.411(b), HHS will send to the journal *Developmental Cell* a notice of ORI's findings and the need for retraction or correction of *Dev Cell*. 2008 Jul;15(1):62-73. doi: 10.1016/j.devcel.2008.05.014.

Dated: August 30, 2023.

**Sheila Garrity,**

Director, Office of Research Integrity, Office of the Assistant Secretary for Health.

[FR Doc. 2023-19086 Filed 9-1-23; 8:45 am]

**BILLING CODE 4150-31-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Institute of Dental and Craniofacial Research; Amended Notice of Meeting**

Notice is hereby given of a change in the meeting of the National Advisory Dental and Craniofacial Research Council, September 12, 2023, 4:45 p.m. to September 13, 2023, 3:30 p.m., National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892, which was published in the **Federal Register** on August 17, 2023, FR Document 2023-17712, 88 FR 56028.

The National Advisory Dental and Craniofacial Research Council Open and Closed Sessions meeting room has changed from the Natcher Building, 45 Center Drive, Bethesda, MD 20892, and will now be held at the John Edward Porter Neuroscience Research Center Building, 35 Convent Drive Room 620/630, Bethesda, MD 20892. Meeting times remain the same. The meeting is partially closed to the public.

Dated: August 29, 2023.

**Melanie J. Pantoja,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-19017 Filed 9-1-23; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HOMELAND SECURITY**

[Docket Number DHS-2023-0020]

**Agency Information Collection Activities: Generic Clearance for Improving Customer Experience (OMB Circular A-11, Section 280 Implementation), 1601-0029**

**AGENCY:** Department of Homeland Security (DHS).

**ACTION:** 30-Day notice and request for comments.

**SUMMARY:** The Department of Homeland Security, DHS will submit the following information collection request (ICR) to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act. DHS previously published this information collection request (ICR) in the **Federal Register** on June 23, 2023, for a 60-day public comment period. No comments were received by DHS. The purpose of this notice is to allow additional 30-days for public comments.

**DATES:** Comments are encouraged and will be accepted until October 5, 2023.